Pharma in Motion: GLP-1 Giants, ADC Breakthroughs, and Workforce Shifts in Late May 2026

The final week of May 2026 delivered a cascade of transformative events across the pharmaceutical landscape. From the European regulator's backing of Novo Nordisk's oral Wegovy and AstraZeneca's Etcamah to the approval of AZ/Daiichi's Datroway in triple-negative breast cancer, the GLP-1 and ADC races intensified. Merck and Kelun's sac-TMT combo posted a stunning 65% PFS advantage over Keytruda, while AbbVie trimmed 85 jobs at an Allergan facility. Meanwhile, Eli Lilly levied fraud accusations against church-linked rebate schemes, and Tyra Biosciences launched a rare cancer awareness day. This analysis unpacks the economic logic, competitive dynamics, and legal undercurrents driving this historic moment.

1. The Week That Reshaped Pharma’s Trajectory

May 21–22, 2026, witnessed a rare convergence of regulatory decisions, clinical data, layoffs, and legal actions that collectively redrew the competitive map of the pharmaceutical industry. The core axis of change is clear: competition in the GLP-1 and ADC classes is accelerating at breakneck speed, even as cost-cutting measures and fraud allegations reveal underlying market stresses.

A dual-track analysis is essential to understand these events. On the fast track, markets reacted within hours to regulatory news such as the EMA’s recommendation of Novo Nordisk’s oral Wegovy pill. On the slow track, structural implications—like Merck and Kelun’s sac-TMT deal reshaping oncology pipelines—will take years to fully materialize. The juxtaposition of breakthrough science and belt-tightening layoffs captures an industry in transition.

[IMAGE: A timeline infographic showing May 21 and 22 events in chronological order, with icons for regulatory approval, clinical data, layoffs, and legal action.]

2. GLP-1 Wars: Oral Wegovy and Etcamah Gain EU Support

On May 22, 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of two major obesity treatments: Novo Nordisk’s oral Wegovy pill and AstraZeneca’s Etcamah (cagrilintide/semaglutide combination). These recommendations mark a turning point in the GLP-1 wars, shifting the battlefield from injectables to oral formulations.

The oral Wegovy pill, based on Novo Nordisk’s proprietary absorption-enhancing technology, offers patients a once-daily tablet alternative to the weekly injection. Clinical trial data submitted to the EMA showed weight loss efficacy comparable to the injectable version, but with significantly higher patient adherence rates—a critical advantage in a market where discontinuation rates for injectable GLP-1s have historically approached 50% after one year.

AstraZeneca’s Etcamah, a dual agonist targeting both the GLP-1 and amylin receptors, represents a differentiated mechanism that could capture a niche in patients with obesity-related cardio-metabolic disorders. The EMA recommendation follows a Phase 3 trial demonstrating superior weight reduction and improved glycemic control compared to semaglutide alone.

Strategic implications are profound. Oral GLP-1s could disrupt the injectable dominance that Novo Nordisk and Eli Lilly have carefully built. Manufacturers with early oral formulations—Novo Nordisk’s pill, Pfizer’s danuglipron, and Lilly’s orforglipron—are now racing to capture the patient population unwilling to use needles. The EMA’s endorsement signals that regulatory pathways for oral peptides are becoming clearer, potentially accelerating timelines for competitors.

[IMAGE: A pill bottle labeled "Wegovy" next to an injection pen, with a European Union flag in the background, symbolizing the oral vs. injectable shift in the EU market.]

3. ADC Breakthroughs: Datroway Approval and sac-TMT’s Keytruda Challenge

The ADC revolution achieved two landmark milestones on May 21–22. First, AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) received regulatory approval in the European Union for first-line treatment of triple-negative breast cancer on May 22. The approval, based on the TROPION-Breast04 trial, showed a statistically significant improvement in progression-free survival over standard chemotherapy in patients with advanced disease.

Second, on May 21, Merck and Kelun-Biotech presented updated data at the ASCO 2026 plenary session showing that their sac-TMT (sacituzumab govitecan plus pembrolizumab) combination achieved a 65% improvement in progression-free survival compared to Keytruda (pembrolizumab) monotherapy in first-line PD-L1-positive non-small cell lung cancer. The hazard ratio of 0.35 (p<0.001) stunned analysts, as it directly challenged the backbone of Merck’s oncology franchise.

The deeper insight here is unmistakable: the ADC and bispecific antibody revolution now threatens PD-1 inhibitors’ supremacy in solid tumors. While Keytruda generated over $25 billion in 2025 sales, the emergence of ADC-based combinations that outperform PD-1 monotherapy could erode that dominance within the next three to five years. Merck’s own investment in Kelun’s ADC pipeline—a $1.4 billion deal in 2025—now looks prescient, but it also creates internal competition with Keytruda.

[IMAGE: A split diagram: left side shows a cancer cell being targeted by an antibody-drug conjugate with a warhead releasing; right side shows a bar chart comparing sac-TMT vs. Keytruda progression-free survival with a 65% difference highlighted.]

4. Workforce Rationalization: AbbVie’s Allergan Layoffs Signal Integration Pain

While scientific breakthroughs dominated headlines, a quieter but significant event unfolded in Irvine, California. AbbVie filed a Worker Adjustment and Retraining Notification (WARN) notice on May 22, announcing the permanent layoff of 85 employees at its Allergan facility, effective July 20, 2026. The affected positions span manufacturing, quality assurance, and administrative support.

The layoffs, though small in absolute numbers, carry symbolic weight. AbbVie acquired Allergan in 2020 for $63 billion, largely to secure Botox and a pipeline of neuroscience and eye care assets. Nearly six years later, the integration continues to generate redundancies. The Irvine facility was a legacy Allergan site specializing in medical aesthetics manufacturing. AbbVie’s decision to trim headcount there likely reflects shifting R&D priorities away from legacy aesthetics toward high-growth areas such as immunology, oncology, and neuroscience.

The hidden pattern is revealing: large pharma companies are aggressively reducing post-merger overlaps even as they pour billions into GLP-1 and ADC pipelines. AbbVie, for example, is simultaneously expanding its obesity pipeline through a partnership with Calibr, while cutting jobs in non-core areas. This dual strategy—investing in innovation while shedding legacy costs—is becoming standard across the industry. Workforce moves often precede larger strategic pivots; investors should watch for further divestitures from AbbVie’s aesthetics portfolio.

[IMAGE: A photo of the Allergan facility in Irvine, California, with a "WARN Notice Filed" overlay and an AbbVie logo, symbolizing post-merger workforce adjustments.]

5. Fraud Allegations and Rare Disease Advocacy: Lilly and Tyra in the Spotlight

The week’s legal and advocacy events added a layer of complexity to the pharma landscape. On May 21, Eli Lilly filed a lawsuit in the U.S. District Court for the Southern District of Indiana accusing a network of church-affiliated organizations of orchestrating a fraudulent rebate scheme. According to the complaint, the defendants allegedly exploited patient assistance programs by submitting falsified claims for Lilly’s insulin products, then pocketing rebates intended for uninsured patients. Lilly alleges damages exceeding $50 million and is seeking treble damages under the Racketeer Influenced and Corrupt Organizations Act.

The lawsuit sheds light on a broader pattern of rebate fraud that has plagued the U.S. drug pricing system. By targeting church-linked intermediaries, Lilly is signaling zero tolerance for schemes that undermine its patient access programs. The legal undercurrent is significant: as drug prices face increasing scrutiny, manufacturers are tightening oversight of third-party entities involved in rebate distribution. This case could set a precedent for how pharma companies police their own patient assistance ecosystems.

On a more positive note, Tyra Biosciences announced on May 22 the inaugural "Rare Cancer Awareness Day," a global initiative to highlight the challenges faced by patients with FGFR-driven cancers. The day coincides with the one-year anniversary of Tyra’s lead asset, TYRA-300, receiving FDA orphan drug designation for advanced urothelial carcinoma. The company plans to fund educational programs and diagnostic funding for underserved regions.

The juxtaposition of fraud allegations and rare disease advocacy highlights the dual nature of pharma’s public image. Companies like Lilly are fighting abuse of their charitable programs, while smaller biotechs like Tyra leverage awareness campaigns to build brand equity and community trust. Both moves, though opposite in tone, share a common goal: protecting and expanding market access in an environment of heightened regulatory and public scrutiny.

[IMAGE: A gavel resting on a courtroom desk next to a church silhouette on the left, and on the right a blue ribbon with "Rare Cancer Awareness Day" text and the Tyra Biosciences logo, illustrating the dual narrative of legal action and advocacy.]

6. The Road Ahead: Convergence and Contradiction

Looking back at the events of May 21–22, 2026, the pharmaceutical industry appears caught between two powerful forces: the pull of scientific innovation and the push of financial discipline. Oral GLP-1s are poised to expand the obesity market beyond the early adopters who tolerate injections. ADC combinations are rewriting oncology treatment paradigms, with the potential to displace blockbuster immunotherapies. Data from Merck and Kelun suggest a new standard of care may be emerging, but it will require significant investment in manufacturing and clinical education.

Meanwhile, workforce rationalization at AbbVie and fraud allegations at Lilly remind investors and executives that growth must be funded by efficiency and integrity. Layoffs, while painful, are part of a necessary restructuring that allows capital to flow toward high-return areas like GLP-1 and ADC development. Legal actions demonstrate that the pricing ecosystem remains fragile, and companies must actively defend the integrity of their programs.

Tyra’s rare disease advocacy offers a glimpse of a more patient-centric future, where even small biotechs can drive meaningful awareness. But the sustainability of such initiatives depends on a regulatory environment that rewards innovation while controlling costs.

For the rest of 2026, watch for three key signals: the EMA’s final approval decision on Wegovy pill and Etcamah (expected within 60 days), the full publication of Merck and Kelun’s ASCO data in a peer-reviewed journal, and further layoff announcements from other large pharma companies as integration cycles complete. The industry is in motion, and those who understand the dual-track logic of fast news and slow structural change will be best positioned to navigate the turbulence ahead.

[IMAGE: A split composition: left side shows a modern pharmaceutical lab with a scientist holding a tablet displaying a chart of tumor shrinkage; right side shows a corporate building with a "For Lease" sign and a gavel in front. In the center, a glowing green pill and a vial of liquid overlay. No text, no watermark, photorealism.]